Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fujirebio, SRL to Consolidate in April 2005
December 27, 2004
- 2004 Spot Test Market Totals \94.4 Bil. in 2003: Fuji-keizai
December 27, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 27, 2004
- Astellas Pharma to Explore Any Possibility to Become a Global Mega Pharma
December 27, 2004
- Norvasc Ranked at Top in 3rd Qtr: IMS Data
December 27, 2004
- Sanofi-Synthelabo, Aventis Pharma to Consolidate Their Businesses in January 2005
December 27, 2004
- Kaken to Make Trafermin Blockbuster by Add. Indication, Formulation
December 27, 2004
- Taisho Starts PI Trials for Antidepressant TS-041
December 27, 2004
- Non-wholesale Business to Account for 50% of Ordinary Profits in 2010: Suzuken
December 27, 2004
- LTT to Start PIIa Trial on PC-SOD in Japan
December 27, 2004
- Wholesalers' Distribution Cost Ratio Higher for Pharmacies: FJPWA Survey
December 27, 2004
- Combinations of Anti-HIV Drugs Increasing : JSAR Meeting
December 27, 2004
- BUSINESS NEWS IN BRIEF
December 27, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 27, 2004
- Press Seminar
December 27, 2004
- GL Prepared for Use of Thalidomide for Multiple Myeloma
December 27, 2004
- Mixed Medical Care to Be Expanded
December 27, 2004
- OTC NEWS IN BRIEF
December 27, 2004
- List of Institutions Which Received Delivery of MPC's Fibrinogen Preparations Published
December 27, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 20, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…